{"schema_version":"secwatch.filing_event.v1","accession":"0001159036-26-000023","form_type":"8-K","ticker":"HALO","cik":"0001159036","company_name":"HALOZYME THERAPEUTICS, INC.","filed_at":"2026-02-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.626274+00:00","generated_at":"2026-05-16T02:20:27.033484+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Halozyme full-year 2025 revenue $1.397B (up 38%), royalty record $868M; 2026 guidance reiterated","bullets":["FY2025 total revenue $1.397B (+38% YoY); royalty revenue $868M (+52%) led by VYVGART Hytrulo, DARZALEX SC, Phesgo.","GAAP net income $316.9M ($2.56 diluted EPS) includes $284.9M IPR&D charge for Surf Bio acquisition; adjusted EBITDA $657.6M.","Q4 2025 revenue $451.8M (+52% YoY); net loss $141.6M due to Surf Bio charge; adjusted EBITDA $21.9M.","2026 guidance: total revenue $1.71–1.81B (growth 22–30%), royalty $1.13–1.17B, adjusted EBITDA $1.125–1.205B, non-GAAP EPS $7.75–8.25.","Expanded delivery portfolio via Elektrofi and Surf Bio acquisitions; completed $1.5B convertible note offering."],"urls":{"canonical":"https://secwatch.observer/filing/0001159036-26-000023","json":"https://secwatch.observer/filing/0001159036-26-000023.json","markdown":"https://secwatch.observer/filing/0001159036-26-000023.md","text":"https://secwatch.observer/filing/0001159036-26-000023.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000023/0001159036-26-000023-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1159036/000115903626000023/halo-20260217.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T02:20:27.033484+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}